News & events Upcoming events Nov 29, 2022 - Dec 2, 2022 CTAD 2022 - 15th Clinical Trials on Alzheimer's Disease Congress San Francisco, United States of America More info and meet us there Dec 7, 2022 - Dec 8, 2022 Congrès des Unités de Soins Alzheimer - USPALZ 2022 Issy-les-Moulineaux (Paris), France More info and meet us there Feb 6, 2023 - Feb 9, 2023 Medlab Middle East 2023 Dubai, United Arab Emirates More info and meet us there See all upcoming events Latest news Jan 18, 2022 Fujirebio Europe launches the RoboBlot™ instrument, a fully automated solution for INNO-LIA® Score assays Gent, Belgium - January 18, 2022: Fujirebio Europe announced today the commercial launch of the RoboBlot instrument, a closed system for the... Read more Nov 19, 2021 Fujirebio Europe confirms engagement in new pathways for Alzheimer’s disease research and launches INNOTEST® assays for the two promising biomarkers NPTX2 and sTREM2 Fujirebio Europe today announced the commercial launch of two new cerebrospinal fluid (CSF) based immunoassays for the novel neurology... Read more Oct 28, 2021 Fujirebio Europe receives translational research funding from Alzheimer’s Drug Discovery Foundation for development of a fully automated plasma pTau181 testing solution H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio, today announced an agreement with the Diagnostics Accelerator... Read more Aug 18, 2021 Fujirebio Europe announces CE marking of the fully automated Lumipulse® G SARS-CoV-2 S-IgG assay Fujirebio Europe announces the CE marking of the Lumipulse G SARS-CoV-2 S-IgG assay, a quantitative antibody assay for a fully automated... Read more Jun 16, 2021 Fujirebio Europe launches iAMP® COVID-19 SANO Assay, a molecular detection assay that can be performed in saliva Gent, Belgium – June 16, 2021: Fujirebio Europe today announced the commercial launch of iAMP COVID-19 SANO (Saliva And Nasopharyngeal... Read more Jan 19, 2021 Statement on the impact of coronavirus disease Covid-19 on our operations The novel coronavirus disease Covid-19 first reported in late 2019 has spread worldwide. At Fujirebio Europe’s Belgian facilities, we are... Read more Load More
Nov 29, 2022 - Dec 2, 2022 CTAD 2022 - 15th Clinical Trials on Alzheimer's Disease Congress San Francisco, United States of America More info and meet us there
Dec 7, 2022 - Dec 8, 2022 Congrès des Unités de Soins Alzheimer - USPALZ 2022 Issy-les-Moulineaux (Paris), France More info and meet us there
Feb 6, 2023 - Feb 9, 2023 Medlab Middle East 2023 Dubai, United Arab Emirates More info and meet us there
Jan 18, 2022 Fujirebio Europe launches the RoboBlot™ instrument, a fully automated solution for INNO-LIA® Score assays Gent, Belgium - January 18, 2022: Fujirebio Europe announced today the commercial launch of the RoboBlot instrument, a closed system for the... Read more
Nov 19, 2021 Fujirebio Europe confirms engagement in new pathways for Alzheimer’s disease research and launches INNOTEST® assays for the two promising biomarkers NPTX2 and sTREM2 Fujirebio Europe today announced the commercial launch of two new cerebrospinal fluid (CSF) based immunoassays for the novel neurology... Read more
Oct 28, 2021 Fujirebio Europe receives translational research funding from Alzheimer’s Drug Discovery Foundation for development of a fully automated plasma pTau181 testing solution H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio, today announced an agreement with the Diagnostics Accelerator... Read more
Aug 18, 2021 Fujirebio Europe announces CE marking of the fully automated Lumipulse® G SARS-CoV-2 S-IgG assay Fujirebio Europe announces the CE marking of the Lumipulse G SARS-CoV-2 S-IgG assay, a quantitative antibody assay for a fully automated... Read more
Jun 16, 2021 Fujirebio Europe launches iAMP® COVID-19 SANO Assay, a molecular detection assay that can be performed in saliva Gent, Belgium – June 16, 2021: Fujirebio Europe today announced the commercial launch of iAMP COVID-19 SANO (Saliva And Nasopharyngeal... Read more
Jan 19, 2021 Statement on the impact of coronavirus disease Covid-19 on our operations The novel coronavirus disease Covid-19 first reported in late 2019 has spread worldwide. At Fujirebio Europe’s Belgian facilities, we are... Read more
